GLP-1
A class of medications used for weight management and diabetes treatment, with representative drugs including semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro). The class has attracted significant attention in recent years due to its clinical efficacy in metabolic conditions.
Timeline (last 90 days)
Research found that overweight and diabetic patients taking GLP-1 drugs have a biological age approximately two to three years younger than people with similar conditions who are not taking the drugs.
The evidence linking GLP-1 and biological age comes from conference reports, is still at an early stage, and requires peer review and larger-scale validation.
It is difficult to distinguish whether the biological age improvement brought about by GLP-1 drugs is a direct effect of the drugs or an indirect result of weight loss and metabolic improvement.
While using GLP-1 drugs for weight loss, muscle mass should be protected through resistance training and adequate protein intake.
Some studies indicate that 25% to 40% of the weight lost by GLP-1 users may come from muscle.
Known common side effects of GLP-1 drugs include gastrointestinal reactions (nausea, vomiting, diarrhea), and some users also report muscle loss and gallbladder problems.
GLP-1 receptor agonists were originally developed as diabetes treatments and work by regulating blood sugar and suppressing appetite.
GLP-1 (glucagon-like peptide-1) is a hormone secreted by the intestine that stimulates insulin secretion, suppresses appetite, and produces protective signals in multiple organs.
Symptoms such as hair loss and nail abnormalities may be the result of the combined effects of rapid weight loss and a sudden reduction in nutritional intake, rather than a direct toxic effect of the drug.
GLP-1 drugs (represented by Ozempic) were originally used to treat type 2 diabetes and gained popularity due to their significant weight-loss effects.
14 more timeline events
All Facts (20)
Semaglutide is a chemically modified long-acting GLP-1 receptor agonist with a half-life of approximately one week, and a once-weekly injection is sufficient to maintain stable blood drug concentrations.
60%UnverifiedThe evidence linking GLP-1 and biological age comes from conference reports, is still at an early stage, and requires peer review and larger-scale validation.
50%UnverifiedIt is difficult to distinguish whether the biological age improvement brought about by GLP-1 drugs is a direct effect of the drugs or an indirect result of weight loss and metabolic improvement.
50%UnverifiedWhile using GLP-1 drugs for weight loss, muscle mass should be protected through resistance training and adequate protein intake.
50%UnverifiedSome studies indicate that 25% to 40% of the weight lost by GLP-1 users may come from muscle.
50%UnverifiedKnown common side effects of GLP-1 drugs include gastrointestinal reactions (nausea, vomiting, diarrhea), and some users also report muscle loss and gallbladder problems.
50%UnverifiedGLP-1 receptor agonists were originally developed as diabetes treatments and work by regulating blood sugar and suppressing appetite.
50%UnverifiedResearch found that overweight and diabetic patients taking GLP-1 drugs have a biological age approximately two to three years younger than people with similar conditions who are not taking the drugs.
50%UnverifiedGLP-1 (glucagon-like peptide-1) is a hormone secreted by the intestine that stimulates insulin secretion, suppresses appetite, and produces protective signals in multiple organs.
50%UnverifiedSymptoms such as hair loss and nail abnormalities may be the result of the combined effects of rapid weight loss and a sudden reduction in nutritional intake, rather than a direct toxic effect of the drug.
50%UnverifiedGLP-1 drugs (represented by Ozempic) were originally used to treat type 2 diabetes and gained popularity due to their significant weight-loss effects.
50%UnverifiedMost of these side effects come from spontaneous user reports rather than rigorous statistics from large-scale clinical trials.
50%UnverifiedBecause hair loss and nail abnormalities are not classified as serious adverse events, they have a lower priority in post-marketing surveillance, resulting in a current lack of systematic data.
50%UnverifiedRecommendations for managing GLP-1 drug side effects include ensuring adequate protein intake, supplementing vitamins and minerals when necessary, and adjusting the pace of weight loss under a doctor's guidance to avoid an overly aggressive rate of weight loss.
50%UnverifiedIn Thompson's clinical endoscopic treatment practice, more than 85% of patients have already used GLP-1.
50%UnverifiedMore than one million people discontinue GLP-1 medications every month, with approximately 30% stopping within the first month and a cumulative total of approximately 50% within one year.
50%UnverifiedA therapy that ablates the duodenal lining to reset the diseased intestinal lining can reduce HbA1c by more than one percentage point, and there is preliminary evidence suggesting it may prevent weight regain after discontinuation of GLP-1.
50%UnverifiedThe drugs Enveda is currently testing cover two directions: treating skin-related diseases and helping patients maintain weight loss after discontinuing GLP-1 class drugs.
50%UnverifiedThe reason for weight rebound after discontinuing GLP-1 drugs is that they do not fundamentally alter the metabolic set point, and after stopping the drugs the body drives weight regain through increased hunger and reduced metabolic rate.
50%UnverifiedClinical studies show that patients regain an average of approximately two-thirds of the weight they lost within one year of stopping GLP-1 drugs.
50%